Meeting
2016 Gastrointestinal Cancers Symposium
Second-line chemotherapy by FOLFIRINOX with unresectable pancreatic cancer (phase I, II study).
Authors
Noritoshi Kobayashi
Department of Oncology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
Noritoshi Kobayashi , Motohiko Tokuhisa , Ayumu Goto , Itaru Endo , Yasushi Ichikawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 297)
DOI
10.1200/jco.2016.34.4_suppl.297
Abstract #
297
Poster Bd #
E21
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Nab-paclitaxel (nab-P) combined with FOLFOX for advanced pancreatic cancer: A phase I study.
First Author: Howard Safran
Poster
2014 Gastrointestinal Cancers Symposium
FOLFOX and nab-paclitaxel (nab-P) for advanced pancreatic cancer: A phase I study.
First Author: Howard Safran
Poster
2022 ASCO Annual Meeting
Regorafenib (REGO) plus FOLFIRINOX as frontline treatment in patients (pts) with RAS-mutated metastatic colorectal cancer (mCRC): A phase I/II, dose-escalation and dose-expansion study.
First Author: Antoine Adenis
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka